SCHEMBL18220129

SCHEMBL18220129

COCCNS(=O)(=O)/C(C#N)=C/c1ccc(-c2ccc3cc(N4CCN(C)CC4)ccc3c2)o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.47
KDM4E B2RXH2 4/20 0.45
HPGD P15428 4/20 0.45
ALDH1A1 P00352 4/20 0.45
GAA P10253 3/20 0.45
MAPT P10636 6/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
USP2 O75604 1/20 0.38
HTT P42858 1/20 0.38
RECQL P46063 1/20 0.38
RXFP1 Q9HBX9 2/20 0.37
OPRM1 P35372 2/20 0.37
OPRD1 P41143 2/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
LMNA P02545 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18220138 0.93 APP (0.46) APPKDM4EHPGDALDH1A1GAA
SCHEMBL24076143 0.92 MAPT (0.44) APPKDM4EHPGDALDH1A1GAA
SCHEMBL18220132 0.92 ALDH1A1 (0.53) APPKDM4EHPGDALDH1A1GAA
SCHEMBL18220142 0.85 ALDH1A1 (0.58) APPKDM4EHPGDALDH1A1GAA
SCHEMBL17120871 0.85 APP (0.36) APPKDM4EHPGDALDH1A1GAA
SCHEMBL18220237 0.85 APP (0.36) APPKDM4EHPGDALDH1A1GAA
SCHEMBL24068226 0.85 MAPT (0.44) APPKDM4EHPGDALDH1A1GAA
SCHEMBL23134343 0.84 APP (0.40) APPKDM4EHPGDALDH1A1GAA
SCHEMBL24076142 0.84 MAPT (0.51) APPKDM4EHPGDALDH1A1GAA
SCHEMBL18220148 0.84 APP (0.43) APPKDM4EHPGDALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885KDM4E 4807/4885HPGD 4282/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885KDM4E 4807/4885HPGD 4282/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA APP 1/4885KDM4E 4804/4885HPGD 4311/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA APP 1/4885KDM4E 4804/4885HPGD 4311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.